HK Stock Market Move | HENLIUS (02696) rose more than 6%, and the application for the first phase of clinical trials of self-developed HLXTEHAase02 was approved.

HENLIUS (02696) rose more than 6%, as of the time of publication, it increased by 5.38%, reaching 73.5 Hong Kong dollars, with a trading volume of 88.997 million Hong Kong dollars. On the news front, on March 31, HENLIUS announced that the Phase 1 clinical trial application (IND) of their independently developed HLXTEHAase02 (recombinant human hyaluronidase injection) has been approved by the National Medical Products Administration (NMPA). The company plans to conduct related clinical trials in China (excluding Hong Kong, Macau, and Taiwan) once conditions are met. HLXTE-HAase02 is a new recombinant human hyaluronidase (rHuPH20) independently developed by the company, intended to promote the diffusion and absorption of subcutaneous injection or infusion drugs. Under physiological conditions, HLXTE-HAase02 can specifically depolymerize subcutaneous tissue hyaluronic acid locally and reversibly, increase the injection volume in subcutaneous tissue, enhance the dispersion and permeability of drugs in subcutaneous tissue, thereby increasing the bioavailability of drugs and improving patient compliance with subcutaneous drug administration. HLXTE-HAase02 is intended for the development of subcutaneous drug products to help these drugs achieve more effective subcutaneous delivery. Non-clinical studies show that HLXTE-HAase02 exhibits enzyme activity comparable to marketed recombinant human hyaluronic acid products.